Hoth Therapeutics, Inc. Stock News

Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense Applications HOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it h...

Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program HOBOKEN, N.J., May 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical compa...

Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space Applications HOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Compan...

Regulatory Clearance in Spain Advances Randomized,  Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment Disruptions NEW YORK, May 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in Spain for its Phase 2a CLEER Tria...

Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 14, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...

Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism) Position GDNF as Next-Generation Therapy for MAFLD and Obesity NEW YORK, April 13, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...

NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu ther...

NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering...